Iovance Biotherapeutics (IOVA) Asset Writedowns and Impairment (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Asset Writedowns and Impairment of -$506000.0 for Q1 2026, down 8333.33% year-over-year from $6145.7 in Q1 2025, and down 113.66% quarter-over-quarter from $3.7 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Asset Writedowns and Impairment (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Asset Writedowns and Impairment for 5 consecutive years, with -$506000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment fell 8333.33% year-over-year to -$506000.0; the TTM figure through Mar 2026 stood at $12.9 million (up 75.59% YoY), while the FY2025 annual figure was $13.4 million, up 82.24% from the prior year.
- Asset Writedowns and Impairment slipped to -$506000.0 in Q1 2026 per IOVA's latest filing, from $3.7 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $8.3 million in Q2 2025 and bottomed at -$506000.0 in Q1 2026.
- Historically, Asset Writedowns and Impairment has averaged $2.6 million across 4 years, with a median of $857000.0 in 2022.
- Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment plunged 49.64% — and 2026, when it slumped 8333.33%.
- Iovance Biotherapeutics' Asset Writedowns and Impairment stood at $83000.0 in 2022, then surged by 8761.45% to $7.4 million in 2024, then slumped by 49.64% to $3.7 million in 2025, then slumped by 113.66% to -$506000.0 in 2026.
- Business Quant data shows IOVA's Asset Writedowns and Impairment at -$506000.0 in Q1 2026, $3.7 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.31 Mn |
| Jun 30, 2026 | 3.31 Mn |
| Mar 31, 2026 | -506,000.00 |
| Mar 31, 2026 | -506,000.00 |
| Dec 31, 2025 | 3.70 Mn |
| Dec 31, 2025 | 3.70 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 8.31 Mn |
| Jun 30, 2025 | 8.31 Mn |
| Mar 31, 2025 | -6,000.00 |
| Mar 31, 2025 | -6,000.00 |
| Dec 31, 2024 | 7.36 Mn |
| Dec 31, 2024 | 7.36 Mn |
| Dec 31, 2022 | 83,000.00 |
| Dec 31, 2022 | 83,000.00 |
| Mar 31, 2022 | 314,000.00 |
| Mar 31, 2022 | 314,000.00 |
| Dec 31, 2011 | 160,036.00 |
| Dec 31, 2011 | 160,036.00 |